Clinical Trials Search Tool

Moderate-to-Severe Psoriasis Study

Disease/Condition: Psoriasis

Location: Portland

Ages: 18+

Enrollment Opens: 02-22-2022

Enrollment Closes: TBD


Decreasing resident memory T cells while increasing clinical durability: higher induction doses of risankizumab for moderate-to-severe plaque psoriasis (KNOCKOUT). One year study requires participants to have had psoriasis for at least six months. Participants cannot have previously been exposed to risankizumab.

Study ID: OMRC-000141

To Enroll: Visit to learn more and fill out contact form, or call 503-245-1525.

Posted by: Oregon Medical Research Center |